Referanslar

• 1. Ferrara JL, Reddy P. Pathophysiology of graft versus-host disease. Semin Hematol 2006;43(1):3-10. google scholar
• 2. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020 Feb;7(2):e157-e167. google scholar
• 3. Carpenter PA, MacMillan ML. Management of acute graft-versus-host disease in children. Pediatr Clin North Am 2010 Feb;57(1):273-95. google scholar
• 4. Patel KK, Patel AK, Ranjan RR, Shah AP. Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an ımmunocompetent patient. Indian J Hematol Blood Transfus 2010 Sep;26(3):92-5. google scholar
• 5. Saffo S, Peng C, Kibbi N, Patel N, Robert ME, Adekolu E, et al. Graftversus- host disease after pancreatic transplantation. ACG Case Rep J 2019 Sep 12;6(9):e00214. google scholar
• 6. Batra A, Cottler-Fox M, Harville T, Rhodes-Clark BS, Makhoul I, Nakagawa M. Autologous graft versus host disease: An emerging complication in patients with multiple myeloma Bone Marrow Res 2014;2014:891427. google scholar
• 7. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012 Jan 5;119(1):296-307. google scholar
• 8. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1966-67;62:21-78. google scholar
• 9. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003 Jul 15;102(2):756-62. google scholar
• 10. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005 Dec;11(12):945-56. google scholar
• 11. Pavletic SZ, Vogelsang GB, Lee SJ. 2014 National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Preface to the series. Biol Blood MarrowTranspl 2015 Mar;21(3):387-8. google scholar
• 12. Apostolova P, Zeiser R. The role of danger signals and ectonucleotidases in acute graft-versus- host disease. Hum Immunol 2016 Nov;77(11):1037-47. google scholar
• 13. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med(Berl) 2011 Sep;89(9):833-45. google scholar
• 14. Reddy P. Pathopysiology of acute graft versus host disease. Hematol Oncol 2003 Dec:21(4):149-61. google scholar
• 15. Sung AD, Chao NJ. Acute graft-versus-host disease: Are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol 2013 Sep;26(3):285-92. google scholar
• 16. Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood 2011 Nov 3;118(18):5011-20. google scholar
• 17. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014 Jul 17;124(3):374-84. google scholar
• 18. Sarantopoulos S, Ritz J. Aberrant B-cell homeostasis in chronic GVHD. Blood 2015 Mar 12;125(11):1703-7. google scholar
• 19. Zeiser R, Blazar BR. Pathophysiology of chronic graft versus host disease and therapeutic targets. N Engl J Med 2017 Dec 28;377(26):2565-2579. google scholar
• 20. Ghimire S, Weber D, Mavin E, Wang, XN, Dickinson, AM, Holler, E. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol 2017 Mar 20;8:79. google scholar
• 21. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, et al. Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone marrow transplantation for acute leukemia: Implications for prophylaxis. Biol Blood MarrowTransplant 2018 Mar;24(3):521-8. google scholar
• 22. Vignon M, Andreoli A, Dhédin N, Lebgline E, Masson E, Robin M, et al. Graft-versus-host disease in adolescents and young adults (15-24 years old) after allogeneic hematopoietic stem cell transplantation for acute leukemia in first complete remission. J Adolesc Young Adult Oncol 2017 Jun;6(2):299-306. google scholar
• 23. Carlberg V, Simons E, Delano S, Huang JT. Pediatric Graft- Versus-Host Diease In: Cotliar JA, eds. Atlas of Graft-Versus-Host Diease: Approaches to Diagnosis and Treatment. Cham, 1st ed. Switzerland: Springer International Publishing AG, 2017:105-23. google scholar
• 24. Gatza E, Reddy P, Choi SW. Prevention and treatment of acute graftversus- host disease in children, adolescents, and young adults. Biol Blood Marrow Transplant 2020 May;26(5):e101-e112. google scholar
• 25. Hosseini E, Schwarer AP, Ghasemzadeh M. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation. Iran J Allergy Asthma Immunol 2012;11(1):15-21. google scholar
• 26. Hosseini E, Schwarer AP, Ghasemzadeh M. Do human leukocyte antigen E polymorphisms influence graft-versus-leukemia after allogeneic hematopoietic stem cell transplantation? Exp Hematol 2015 Mar;43(3):149-57. google scholar
• 27. The IMGT/HLA Database; http://www.ebi.ac.uk/imgt/hla/stats. html Erişim tarihi: 27.03.2014 google scholar
• 28. Meyer D, Aguriar VRC, Bitarello BD, Brandt DYC, Nunes K. A genomic perspective on HLA evolution. Immunogenetics 2018 Jan;70(1):5-27. google scholar
• 29. Edgerly CH, Weimer ET. The Past, present, and future of HLA typing in transplantation. Methods Mol Biol 2018;1802:1-10. google scholar
• 30. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor recipient HLA matching contributest othe success of unrelated donor marrow transplantation. Blood 2007 Dec 15;110(13):4576-83. google scholar
• 31. Touzeau C, Gagne K, Sebille V, Herry P, Chevallier P, Follea G, et al. Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study. Hum Immunol 2012 Jul;73(7):711-4. google scholar
• 32. Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009 Aug 13;114(7):1437-44. google scholar
• 33. Rene C, Lozano C, Eliaou JF. Expression of classical HLA class I molecules: regulation and clinical impacts: Julia Bodmer award review 2015. HLA 2016 May;87(5):338-49. google scholar
• 34. Summers C, Sheth VS, Bleakley M. Minor histocompatibility antigen-specific T cells. Front Pediatr 2020 Jun3;8:284. google scholar
• 35. Roy DC, Perreault C. Major vs minor histocompatibility antigens. Blood 2017 Feb 9;129(6):664-6. google scholar
• 36. Akatsuka Y, Warren EH, Gooley TA, Brickner AG, Lin MT, Hansen JA, et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 2003 Nov;123(4):671-5. google scholar
• 37. McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet 2009 Dec;41(12):1341-4. google scholar
• 38. Martin PJ, Levine DM, Storer BE, Warren EH, Zheng X, Nelson SC et al. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood 2017 Feb 9;129(6):791-8. google scholar
• 39. Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM, et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005 Dec 15;106(13):4407-11. google scholar
• 40. Henden AS, Hill GR. Cytokines in graft-versus-host disease. J Immunol 2015 May 15;194(10):4604-12. google scholar
• 41. Kumar S, Mohammadpour H, Cao X. Targeting cytokines in GVHD therapy. J Immunol Res Ther 2017;2(1):90-9. google scholar
• 42. Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, et al. Reciprocal differentiation and tissue- specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009 Oct 1;114(14):3101-12. google scholar
• 43. Hüber CM, Doisne JM, Colucci F. IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation. Eur J Immunol 2015 Jun;45(6):1727-35. google scholar
• 44. Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY, et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 2005 Apr 15;105(8):3372-80. google scholar
• 45. Zeiser R, Blazar BR. Acute graft versus host disease-biologic process, prevention and therapy. N Engl J Med 2017 Nov 30;377(22):2167- 79. google scholar
• 46. Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 2019 Jan;25(1):94-9. google scholar
• 47. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman E, et al. PD-1 blockade for relapsed lymphoma postallogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 2017 Jul 13;130(2):221-8. google scholar

Atıflar